Elan enters $1B royalty deal with Theravance

by The Associated Press

Irish drugmaker Elan Corp. PLC plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance Inc. and GlaxoSmithKline.

The deal announced Monday will give Elan 21 percent of the future royalties that South San Francisco, California-based Theravance receives from Glaxo, a British drugmaker.

Theravance shares climbed $5.62, or 16.1 percent, to $40.56 in afternoon trading. Earlier the stock reached an all-time high of $40.70.

Drugs named in the deal include Breo Ellipta, a once-a-day inhaled treatment that just received approval from the U.S. Food and Drug Administration, and two treatments that have entered late-stage testing. The treatments also include Anoro Ellipta, for which the drugmakers have filed for regulatory approval in both the United States and Europe.

On Friday, the U.S. Food and Drug Administration said it approved Breo Ellipta for long-term use and to control flare-ups in patients with chronic obstructive pulmonary disorder, often called smoker's cough. The drug will be named Relvar Ellipta in Europe, where regulators are still reviewing it.

The companies expect to close the royalty agreement at the end of June if Elan shareholders approve it. Elan plans to use 20 percent of the sales it receives from this agreement to pay shareholders a cash dividend.

Elan has recently received takeover bids from Royalty Pharma, a private, New York-based company that buys royalty interests in drugs and late-stage drug candidates.

Royalty offered in February to buy Elan for $11 per share, or about $6.5 billion. It later raised that offer to $11.25 per share, or about $6.7 billion. Last month, Elan said its board unanimously rejected the takeover bid, with company leaders saying the price was too low.

U.S.-traded shares of Elan lost 24 cents, or 2.1 percent, to $11.54.

Moody's Investors Service said Monday that it is placing Elan's credit ratings on review for a possible downgrade. Moody's said Elan has spent a lot of cash recently without getting back anything that will generate immediate earnings or cash flow. The firm currently rates Elan's credit at 'Ba3'. That rating is non-investment grade, three notches into "junk" status.

"Although Breo Elipta could become a blockbuster, its rate of market acceptance is not certain and substantial returns to Elan could be protracted," said analyst Michael Levesque.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

US panel backs inhaler drug for lung disease

Apr 17, 2013

A panel of U.S. respiratory experts voted Wednesday in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravance for treating chronic lung disease.

Elan moves to deter takeover bid

Mar 04, 2013

(AP)—Irish drug maker Elan Corp. announced Monday it will pay shareholders a recurring special dividend linked to the sales of the multiple sclerosis treatment Tysabri.

Drugmaker GSK posts slumping Q1 profits

Apr 24, 2013

British drugs firm GlaxoSmithKline on Wednesday said its first-quarter net profit tumbled by almost a third, with the group hit by falling sales and a poor economic climate.

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments